시장보고서

상품코드

1771483

미국의 대동맥 장골 폐색 질환 치료 시장 : 규모, 점유율, 동향 분석(기기유형별, 처치별, 최종 용도별), 부문별 예측(2025-2030년)

U.S. Aorto-iliac Occlusive Disease Treatment Market Size, Share & Trends Analysis Report By Device Type, By Procedure, By End-use, And Segment Forecasts, 2025 - 2030

발행일: 2025년 06월 | 리서치사:

Grand View Research | 페이지 정보: 영문 100 Pages | 배송안내 : 2-10일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

시장 규모와 동향 :

미국 대동맥 장골 폐색 질환 치료 시장 규모는 2024년 7억1,660만 달러로 평가되었고, 2025년부터 2030년까지 연평균 복합 성장률(CAGR) 5.4%로 성장할 것으로 예측됩니다. PAD 이환율 증가, 정부의 이니셔티브의 높아짐, 기술의 진보가 시장 성장의 원동력이 되고 있습니다.

이 장치는 PAD와 대동맥 장골 폐색 질환에 흔한 심각한 석회화 병변을 치료하기 위해 설계되었습니다. 루이지애나에 있는 남부 심혈관 연구소에서 실시된 첫 번째 성공적인 환자 시술은 이 장치가 복잡한 개입을 간소화하고 절차적 결과를 개선할 수 있는 잠재력을 보여줍니다. 2023년 6월에 발표된 정부 기사에 따르면, 미국 정부는 동맥 및 정맥 종합법(ARC)의 도입을 통해 대동맥-장골 폐색 질환의 주요 원인인 말초동맥질환(PAD)의 조기 발견 및 관리를 강화하기 위한 중요한 조치를 취했습니다.

대상 진단법에는 발관절 상완혈압비(ABI) 검사와 동맥 듀플렉스 스캔이 포함되며, 이들은 PAD를 확인하고 대동맥-장골 영역의 질환의 중증도를 평가하기 위해 중요합니다. 2024년부터 2028년까지 연간 600만 달러의 자금을 지원하도록 승인된 ARC 법안은 조기 진단 및 적시 개입을 개선하여 진행성 폐쇄성 질환의 부담을 잠재적으로 줄이고 장골 스텐트 삽입술 및 혈관 재개통 요법과 같은 표적 치료 옵션에 대한 수요를 높이는 것을 목표로 합니다.

외래수술센터(ASC) 및 OBL(Office-based Lab)의 미국 전역에의 보급은 대동맥 장골 폐색 질환을 포함한 혈관 인터벤션의 수기 건수 증가에 크게 기여하고 있습니다. 사지를 제공하고 환자를 신속하게 치료하고 비용을 절감하며 환자와 의사 모두에게 유연한 스케줄링을 가능하게합니다. 동맥 인터벤션은 특히 조기부터 중등도의 병기 환자에 대해 ASC와 OBL에서 자주 발생합니다. 절차 위험을 줄이기 위해 이러한 시설에 적합합니다. 이러한 센터로의 전환은 유리한 진료 보상 정책에도 도움이 되며 의료 제공업체와 지불자에게 선호되는 치료 장소입니다.

미국의 대동맥 장골 폐색 질환 치료 시장 : 대시보드, 기기유형별
미국의 대동맥 장골 폐색 질환 치료 시장 : 변동 분석, 기기유형별
미국의 대동맥 장골 폐색 질환 치료 시장 :수익, 기기유형별
혈관내 디바이스
- 풍선 혈관 성형술 장치
- 아테롬 절제 시스템
- 스텐트
외과용 기기

제5장 미국의 대동맥 장골 폐색 질환 치료 시장 : 처치별 추정·동향 분석

미국의 대동맥 장골 폐색 질환 치료 시장 : 대시보드, 처치별
미국의 대동맥 장골 폐색 질환 치료 시장 : 변동 분석, 처리별
미국의 대동맥 장골 폐색 질환 치료 시장 : 수익, 처리별
혈관내 수술
- 풍선 혈관 성형술
- 1차 스텐트 유치술
- 키싱 스텐트
- 커버 부착 스텐트 그래프트
- 혈관내 대동맥 수복술(EVAR)
하이브리드 수술
수술 수술

제6장 미국의 대동맥 장골 폐색 질환 치료 시장 : 최종 용도별 추정·동향 분석

미국의 대동맥 장골 폐색 질환 치료 시장 : 대시보드, 최종 용도별
미국의 대동맥 장골 폐색 질환 치료 시장 : 변동 분석, 최종 용도별
미국의 대동맥 장골 폐색 질환 치료 시장 : 수익, 최종 용도별
병원
외래시설
기타

제7장 경쟁 구도

주요 제조업체에 의한 최근의 동향과 영향 분석
기업/경쟁의 분류
벤더 상황
- 주요 기업의 시장 점유율 분석(2024년)
기업 프로파일
- BD
- Abbott
- Boston Scientific Corporation
- WL Gore &Associates, Inc.
- Medtronic
- Cook
- Terumo Corporation
- Getinge AB

SHW 25.07.21

Market Size & Trends:

The U.S. aorto-iliac occlusive disease (iliac disease) treatment market size was estimated at USD 716.6 million in 2024 and is projected to grow at a CAGR of 5.4% from 2025 to 2030. Increasing PAD incidence, rising government initiatives, and technological advancements drive market growth. For instance, in November 2024, Philips recently launched the THOR IDE clinical trial in the U.S. to evaluate a novel hybrid catheter system that combines laser atherectomy and intravascular lithotripsy.

The device is designed to treat severely calcified lesions commonly found in PAD and aorto-iliac disease. The first successful patient procedure, conducted at the Cardiovascular Institute of the South in Louisiana, demonstrates the potential for this device to streamline complex interventions and improve procedural outcomes. Increasing government initiatives drive market growth. According to the Congress.Gov article published in June 2023, the U.S. government took a significant step toward enhancing early detection and management of Peripheral Artery Disease (PAD), a primary contributor to Aorto-Iliac Occlusive Disease, through the introduction of the Arterial and Venous Comprehensive (ARC) Act. This legislation proposes amendments to the Social Security Act, aiming to ensure that Medicare and Medicaid beneficiaries identified as high-risk can access PAD screening without incurring out-of-pocket costs.

Covered diagnostic procedures include ankle-brachial index (ABI) tests and arterial duplex scans, which are critical for identifying PAD and assessing disease severity in the aorto-iliac region. Authorizing USD 6 million in annual funding from 2024 to 2028, the ARC Act seeks to improve early diagnosis and timely intervention, potentially reducing the burden of advanced occlusive conditions and boosting the demand for targeted treatment options such as iliac stenting and revascularization therapies. This initiative promotes preventive care and supports broader access to essential vascular health services.

The proliferation of ambulatory surgical centers (ASCs) and office-based labs (OBLs) across the U.S. significantly contributes to the growth in procedural volumes for vascular interventions, including those for aorto-iliac occlusive disease. These facilities offer a cost-effective and convenient alternative to traditional hospital settings, enabling quicker patient turnaround, reduced overhead costs, and enhanced scheduling flexibility for both patients and physicians. As a result, iliac artery interventions-such as balloon angioplasty, stenting, and atherectomy are increasingly being performed in ASCs and OBLs, especially for patients presenting with early to moderate stages of the disease. These minimally invasive procedures can often be completed on an outpatient basis, making them well-suited to these settings where shorter recovery times and lower procedural risk are prioritized. The shift toward these centers is also supported by favorable reimbursement policies, making them a preferred site of care for providers and payers.

U.S. Aorto-iliac Occlusive Disease Treatment Market Report Segmentation

This report forecasts revenue growth at a country level and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the U.S. aorto-iliac occlusive disease (iliac disease) treatment market report based on device type, procedure, and end-use:

Device Type Outlook (Revenue, USD Million, 2018 - 2030)
Endovascular Devices
- Balloon Angioplasty Devices
- Atherectomy Systems
- Stents
- Self-Expanding Stents
- Balloon-Expandable Stents
- Covered Stent Grafts
- Bifurcated Aortic Stent Grafts
Surgical Devices
Procedure Outlook (Revenue, USD Million, 2018 - 2030)
Endovascular Procedures
- Balloon Angioplasty
- Primary Stenting
- Kissing Stents
- Covered Stent Grafts
- Endovascular Aortic Repair (EVAR)
Hybrid Procedures
Open Surgical Procedures
End-use Outlook (Revenue, USD Million, 2018 - 2030)
Hospitals
Outpatient Facilities
Others

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope
1.2. Segment Definitions
- 1.2.1. Device Type
- 1.2.2. Procedure
- 1.2.3. End Use
- 1.2.4. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR's internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
1.5. Information or Data Analysis
- 1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
- 1.7.1. Volume price analysis (Model 1)
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
- 2.2.1. Device Type outlook
- 2.2.2. Procedure outlook
- 2.2.3. End Use outlook
2.3. Competitive Insights

Chapter 3. U.S. Aorto-Iliac Occlusive Disease (Iliac Disease) Treatment Market Variables, Trends & Scope

3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
- 3.2.1. Market driver analysis
  - 3.2.1.1. Rising prevalence of peripheral artery disease (PAD)
  - 3.2.1.2. Advancements in endovascular technologies
  - 3.2.1.3. Shift towards in minimally invasive procedures
- 3.2.2. Market restraint analysis
  - 3.2.2.1. Product recalls
  - 3.2.2.2. Clinical complexity and procedural risks
3.3. U.S. Aorto-Iliac Occlusive Disease (Iliac Disease) Treatment Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
  - 3.3.1.1. Supplier power
  - 3.3.1.2. Buyer power
  - 3.3.1.3. Substitution threat
  - 3.3.1.4. Threat of new entrant
  - 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
  - 3.3.2.1. Political landscape
  - 3.3.2.2. Technological landscape
  - 3.3.2.3. Economic landscape

Chapter 4. U.S. Aorto-Iliac Occlusive Disease (Iliac Disease) Treatment Market: Device Type Estimates & Trend Analysis

4.1. U.S. Aorto-Iliac Occlusive Disease (Iliac Disease) Treatment Market: Device Type Dashboard
4.2. U.S. Aorto-Iliac Occlusive Disease (Iliac Disease) Treatment Market: Device Type Movement Analysis
4.3. U.S. Aorto-Iliac Occlusive Disease (Iliac Disease) Treatment Market by Device Type, Revenue
4.4. Endovascular Devices
- 4.4.1. Market estimates and forecast, 2018 - 2030 (USD Million)
- 4.4.2. Balloon Angioplasty Devices
  - 4.4.2.1. Market estimates and forecast, 2018 - 2030 (USD Million)
- 4.4.3. Atherectomy Systems
  - 4.4.3.1. Market estimates and forecast, 2018 - 2030 (USD Million)
- 4.4.4. Stents
  - 4.4.4.1. Market estimates and forecast, 2018 - 2030 (USD Million)
  - 4.4.4.2. Self-expanding Stents
    - 4.4.4.2.1. Market estimates and forecast, 2018 - 2030 (USD Million)
  - 4.4.4.3. Balloon-expandable Stents
    - 4.4.4.3.1. Market estimates and forecast, 2018 - 2030 (USD Million)
  - 4.4.4.4. Covered stent grafts
    - 4.4.4.4.1. Market estimates and forecast, 2018 - 2030 (USD Million)
  - 4.4.4.5. Bifurcated aortic stent grafts
    - 4.4.4.5.1. Market estimates and forecast, 2018 - 2030 (USD Million)
4.5. Surgical Devices
- 4.5.1. Market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 5. U.S. Aorto-Iliac Occlusive Disease (Iliac Disease) Treatment Market: Procedure Estimates & Trend Analysis

5.1. U.S. Aorto-Iliac Occlusive Disease (Iliac Disease) Treatment Market: Procedure Dashboard
5.2. U.S. Aorto-Iliac Occlusive Disease (Iliac Disease) Treatment Market: Procedure Movement Analysis
5.3. U.S. Aorto-Iliac Occlusive Disease (Iliac Disease) Treatment Market by Procedure, Revenue
5.4. Endovascular Procedures
- 5.4.1. Market estimates and forecast, 2018 - 2030 (USD Million)
- 5.4.2. Balloon Angioplasty
  - 5.4.2.1. Market estimates and forecast, 2018 - 2030 (USD Million)
- 5.4.3. Primary Stenting
  - 5.4.3.1. Market estimates and forecast, 2018 - 2030 (USD Million)
- 5.4.4. Kissing Stents
  - 5.4.4.1. Market estimates and forecast, 2018 - 2030 (USD Million)
- 5.4.5. Covered Stent Grafts
  - 5.4.5.1. Market estimates and forecast, 2018 - 2030 (USD Million)
- 5.4.6. Endovascular Aortic Repair (EVAR)
  - 5.4.6.1. Market estimates and forecast, 2018 - 2030 (USD Million)
5.5. Hybrid Procedures
- 5.5.1. Market estimates and forecast, 2018 - 2030 (USD Million)
5.6. Surgical Procedures
- 5.6.1. Market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 6. U.S. Aorto-Iliac Occlusive Disease (Iliac Disease) Treatment Market: End Use Estimates & Trend Analysis

6.1. U.S. Aorto-Iliac Occlusive Disease (Iliac Disease) Treatment Market: End Use Dashboard
6.2. U.S. Aorto-Iliac Occlusive Disease (Iliac Disease) Treatment Market: End Use Movement Analysis
6.3. U.S. Aorto-Iliac Occlusive Disease (Iliac Disease) Treatment Market by End Use, Revenue
6.4. Hospitals
- 6.4.1. Market estimates and forecast, 2018 - 2030 (USD Million)
6.5. Outpatient Facilities
- 6.5.1. Market estimates and forecast, 2018 - 2030 (USD Million)
6.6. Others
- 6.6.1. Market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

7.1. Recent Developments & Impact Analysis, By Key Manufacturers
7.2. Company/Competition Categorization
7.3. Vendor Landscape
- 7.3.1. Key company market share analysis, 2024
7.4. Company Profiles
- 7.4.1. BD
  - 7.4.1.1. Company overview
  - 7.4.1.2. Financial performance
  - 7.4.1.3. Product benchmarking
  - 7.4.1.4. Strategic initiatives
- 7.4.2. Abbott
  - 7.4.2.1. Company overview
  - 7.4.2.2. Financial performance
  - 7.4.2.3. Product benchmarking
  - 7.4.2.4. Strategic initiatives
- 7.4.3. Boston Scientific Corporation
  - 7.4.3.1. Company overview
  - 7.4.3.2. Financial performance
  - 7.4.3.3. Product benchmarking
  - 7.4.3.4. Strategic initiatives
- 7.4.4. W. L. Gore & Associates, Inc.
  - 7.4.4.1. Company overview
  - 7.4.4.2. Financial performance
  - 7.4.4.3. Product benchmarking
  - 7.4.4.4. Strategic initiatives
- 7.4.5. Medtronic
  - 7.4.5.1. Company overview
  - 7.4.5.2. Financial performance
  - 7.4.5.3. Product benchmarking
  - 7.4.5.4. Strategic initiatives
- 7.4.6. Cook
  - 7.4.6.1. Company overview
  - 7.4.6.2. Financial performance
  - 7.4.6.3. Product benchmarking
  - 7.4.6.4. Strategic initiatives
- 7.4.7. Terumo Corporation
  - 7.4.7.1. Company overview
  - 7.4.7.2. Financial performance
  - 7.4.7.3. Product benchmarking
  - 7.4.7.4. Strategic initiatives
- 7.4.8. Getinge AB
  - 7.4.8.1. Company overview
  - 7.4.8.2. Financial performance
  - 7.4.8.3. Product benchmarking
  - 7.4.8.4. Strategic initiatives